Announcements - OBI Pharma

2026.Sep.10

The Company’s BOD approved to in-license antibody sequences from an U.S. university to strengthen OBI’s next-generation ADC pipeline

2026.Sep.10

The Company’s Board of Directors resolved to revise 2026 Employee Stock Option Issuance and Subscription Rules

2026.Aug.21

Announcement of Changes in the Company’s Internal Audit Officer

2026.Aug.12

The Company’s Board of Directors resolved to issue 2026 employee stock options and the subscription rules

2026.Aug.12

The Company’s BOD resolved to forfeit the subscription of OBIGEN Pharma’s cash capital increase and distribute the rights to its shareholders

2026.Aug.12

Announcement of the Company’s new appointment of financial and corporate governance officer

2026.Aug.12

Announcement of the Company’s new appointment of acting spokesperson

2026.Aug.12

Announcement of the Consolidated Financial Statements for the second quarter of 2026 were approved by the Board of Directors

2026.Aug.04

Announcement of Changes in the Company’s COO, Financial Officer, Corporate Governance Officer, and Acting Spokesperson

2026.Aug.04

Announcement for the expected date of the Board of Directors Meeting for 2026Q2 consolidated financial report is 2026/08/12

News

Latest News

Events

Latest events